NewsSource: EClinCloud

Invitation | Shenzhen, February 29: Join EClinCloud to Discuss Accelerating Clinical Drug Research and Improving R&D Success Rates

6 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.



As the Year of the Dragon begins, EClinCloud looks forward to meeting with you again!
On February 29, join EClinCloud, R&G PharmaStudies, and partners in Shenzhen
Discussing strategies for clinical drug research and drug development
At the event,
Dr. Qin Long, Founder & CEO of EClinCloud, will deliver a keynote presentation
We sincerely welcome your attendance!





Event Information




Guiding Organizations: Chinese Society of Biotechnology, Shenzhen Pingshan District Science and Technology Innovation Bureau

Organizers: R&G PharmaStudies, EClinCloud, Shenzhen Biomedicine Innovations Industrial Park, Shenzhen Pingshan District Biomedical Industry Innovation Chain Party Committee, Huoshi Shulian

Date and Time: Thursday, February 29, 2024, 13:30-17:00

Venue: Lecture Hall, Floor 4, Building 4, Shenzhen Biomedicine Innovations Industrial Park, No. 14 Jinhui Road, Pingshan District, Shenzhen

Article image

Article image
Press and hold to scan and register
February 29, 13:30-17:00
First Stop of the New Year: "Shenzhen"







Agenda





13:30-13:40

Leadership Remarks


13:40-14:10

Model-Informed Drug Development

Hu Bei Chief Clinical Pharmacologist, R&G PharmaStudies; Founder, Lingchu Pharma


14:10-14:40

Begin with the End in Mind: Interpreting Regulatory Review Flexibility from a Clinical Value Perspective

Li Jigang Chief Medical Officer, R&G PharmaStudies


14:40-15:10

Begin with the End in Mind: Enabling More Accurate Clinical Outcome Assessment (COA) Through Digitalization and Intelligence

Qin Long, Founder & CEO, EClinCloud


15:10-15:40

Introduction to New Drug Registration in the EU and Key Considerations

Qiu Jiancheng Vice President and Head of Regulatory Affairs (RA), R&G PharmaStudies


15:40-16:10

Early Prediction of Human PK and Dose Based on ADME Characteristics of Innovative Drugs

Gao Zhiwei General Manager, Shanghai Hengling Pharmaceutical Technology Co., Ltd.


16:10-16:50

Panel Discussion: How to Accelerate Clinical Drug Research and Improve Drug R&D Success Rates?

Moderator: Li Jigang, Chief Medical Officer, R&G PharmaStudies

Panelists:

Chen Gang, Chief Scientific Officer, R&G PharmaStudies

Hu Bei, Chief Clinical Pharmacologist, R&G PharmaStudies

Qiu Jiancheng, Vice President, R&G PharmaStudies

Qin Long, Founder & CEO, EClinCloud

Gao Zhiwei, General Manager, Shanghai Hengling Pharmaceutical Technology Co., Ltd.


16:50-17:00

Q&A






Speaker Profiles







Article image

Chen Gang

Chief Scientific Officer, R&G PharmaStudies

  • Ph.D. in Statistics, University of Maryland, USA, with 30+ years of biostatistics experience at the U.S. FDA and in the pharmaceutical industry;
  • Previously served as Senior Statistical Reviewer and Division Director in the biostatistics division of the U.S. FDA's oncology drug review center, and as Head of Clinical Biostatistics for Oncology Drug R&D at Johnson & Johnson (U.S.) and Head of Quantitative Sciences at Johnson & Johnson (China);
  • Founder of Aikeman Information Technology Co., Ltd., a subsidiary of R&G PharmaStudies.




Article image

Hu Bei

Chief Clinical Pharmacologist, R&G PharmaStudies; Founder, Lingchu Pharma
  • M.D., Peking Union Medical College; Postdoctoral Fellow, Department of Medicinal Chemistry, University of Washington, USA; formerly Doctoral Advisor and Professor of Clinical Pharmacology at Peking Union Medical College Hospital;

  • 30+ years of experience in clinical pharmacology teaching, practice, and clinical research on innovative drugs, having participated in 100+ Phase I/II clinical trials of innovative drugs and published 130+ SCI articles;

  • Currently Chief Clinical Pharmacologist at R&G PharmaStudies and Founder of its subsidiary Lingchu Pharmaceutical Technology Co., Ltd.




Article image

Li Jigang

Chief Medical Officer, R&G PharmaStudies

  • Master's degree in Pathology, University of Rochester (USA);
  • 16 years of experience in clinical R&D and medical affairs at Johnson & Johnson and R&G PharmaStudies;
  • Led R&D strategies for 50+ innovative drugs across multiple therapeutic areas, including CNS, hematology, oncology, immunology, cardiovascular, and endocrinology.




Article image

Qin Long

Founder and CEO, EClinCloud

  • Ph.D. in Management, Beihang University; postdoctoral research in medical statistics, Sun Yat-sen University.

  • Over 17 years of experience in the clinical research industry, and a pioneer in China in applying new IT technologies to improve the quality and efficiency of clinical trials;

  • An innovative and inspiring leader, and a pioneer in promoting and implementing technology solutions such as eCOA, EDC, and CTMS in China's clinical research field;

  • Previously served as Asia-Pacific head of an international technology company, leading rapid business growth across the region;

  • An entrepreneur driven by academia and science, dedicated with great passion to shaping future clinical trial models.





Article image

Qiu Jiancheng

Vice President and Head of Regulatory Affairs (RA), R&G PharmaStudies

  • Master's degree in Pharmaceutics, Academy of Military Medical Sciences; 18 years of experience in drug and medical device registration and regulatory affairs;
  • Previously held positions at well-known pharmaceutical companies including Novartis, Sanofi (Genzyme), and Clinipace, serving as (Senior) Regulatory Affairs Manager, Regulatory Affairs Director, and Head of Asia-Pacific Regional Regulatory Affairs.




Article image

Gao Zhiwei

General Manager, Shanghai Hengling Pharmaceutical Technology

  • Ph.D. in Clinical Pharmacology, Fudan University; Youth Committee Member of the Drug Metabolism Professional Committee, Chinese Pharmacological Society.
  • Co-founded Shanghai Hengling Pharmaceutical Technology Co., Ltd. in October 2019;
  • 2006–2019: Research on pharmacokinetics and drug metabolism of innovative drugs, Shanghai Institute of Materia Medica, Chinese Academy of Sciences;
  • 17 years of experience in ADME research on innovative drugs and specialty formulations, having participated in completing ADME evaluations for 280+ innovative drugs, with over 200 approved to enter clinical trials and 10 new drugs approved for marketing;
  • Specializes in PK data analysis and PBPK modeling, and has published 18 SCI papers;
  • Contributing author to the monograph "Research on Metabolism and Pharmacokinetics of Innovative Drugs".




2024 R&G PharmaStudies Park Tour, Stop 1: Shenzhen Biomedical Innovation Industrial Park





In 2024, the R&G PharmaStudies Park Tour sets off again with a full upgrade, partnering for its first stop with Shenzhen Biomedical Innovation Industrial Park, EClinCloud, and Huoshi Shulian to head to Shenzhen.

For any pharmaceutical company, advancing a drug candidate into Phase I clinical trials after rigorous optimization in the preclinical stage is a major achievement. However, once in clinical research, nine out of ten drug candidates fail during Phase I, II, and III clinical trials and the drug approval process. It is also worth noting that this 90% failure rate applies to drug candidates that have already entered Phase I clinical trials and does not include those still in the preclinical stage.

Centered on the theme "How to Accelerate Clinical Drug Research and Improve the Success Rate of Drug R&D?", this R&G PharmaStudies Park Tour event invites R&G PharmaStudies Chief Scientific Officer Dr. Chen Gang, Chief Clinical Pharmacologist Prof. Hu Bei, Chief Medical Officer Mr. Li Jigang, and Vice President Mr. Qiu Jiancheng, as well as EClinCloud Founder and CEO Dr. Qin Long and Shanghai Hengling Pharmaceutical Technology General Manager Mr. Gao Zhiwei, to provide in-depth analysis and presentations on innovative drug clinical research strategies, top-level design, regulatory review and approval focus areas, and the application of digital technologies, empowering clinical research for innovative pharmaceutical companies in Shenzhen.



We sincerely welcome your attendance and look forward to sharing the highlights of the event with you on site!







About EClinCloud

EClinCloud is a technology company focused on clinical R&D. It provides an integrated, interoperable, all-in-one clinical trial cloud platform (including solutions across technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, covering scale design, scale copyright management, linguistic validation, rater training, and data quality analysis, among others) as well as clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system and ophthalmology, among others). By combining cutting-edge technology with life data, it is building a globally leading, patient-centric SaaS cloud platform for clinical evidence support to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and devices, and benefit countless patients.







Article image

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.